DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company operates DaVita Rx, a pharmacy that provides oral medications and medication management services to patients with ESRD; disease management services; vascular access services; clinical research programs; physician services; and direct primary care services. As of December 31, 2017, it provided dialysis and administrative services in the United States through a network of 2,510 outpatient dialysis centers serving approximately 197,800 patients; and operated 237 outpatient dialysis centers located in 11 countries outside of the United States. Further, the company provides acute inpatient dialysis services in approximately 900 hospitals and related laboratory services in the United States. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was founded in 1994 and is headquartered in Denver, Colorado.
Industry, Sector and Symbol
Stock Exchange NYSE
Industry Miscellaneous health & allied services, not elsewhere classified
Sub-IndustryHealth Care Services
SectorMedical
Current SymbolNYSE:DVA
Previous Symbol
CUSIP23918K10
Phone303-405-2100
Debt
Debt-to-Equity Ratio2.09
Current Ratio1.84
Quick Ratio1.82
Price-To-Earnings
Trailing P/E Ratio18.50
Forward P/E Ratio17.26
P/E Growth0.83
Sales & Book Value
Annual Sales$10.88 billion
Price / Sales0.94
Cash Flow$7.5852 per share
Price / Cash8.10
Book Value$26.66 per share
Price / Book2.30
Profitability
EPS (Most Recent Fiscal Year)$3.32
Net Income$663.61 million
Net Margins5.39%
Return on Equity13.87%
Return on Assets3.29%
Miscellaneous
Employees74,500
Outstanding Shares166,000,000
Market Cap$10.36 billion
OptionableOptionable
Davita (NYSE:DVA) Frequently Asked Questions
What is Davita's stock symbol?
Davita trades on the New York Stock Exchange (NYSE) under the ticker symbol "DVA."
How will Davita's stock buyback program work?
Davita declared that its board has approved a share repurchase plan on Wednesday, October 11th 2017, which allows the company to buyback $1,500,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization allows the company to buy shares of its stock through open market purchases. Shares buyback plans are often a sign that the company's board believes its stock is undervalued.
How were Davita's earnings last quarter?
Davita Inc (NYSE:DVA) announced its quarterly earnings data on Wednesday, November, 7th. The company reported $0.56 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.89 by $0.33. The firm had revenue of $2.85 billion for the quarter, compared to analyst estimates of $2.93 billion. Davita had a return on equity of 13.87% and a net margin of 5.39%. The company's quarterly revenue was up 3.0% on a year-over-year basis. During the same period in the previous year, the company earned $0.81 earnings per share. View Davita's Earnings History.
When is Davita's next earnings date?
What price target have analysts set for DVA?
10 equities research analysts have issued 1-year target prices for Davita's stock. Their forecasts range from $64.00 to $97.00. On average, they expect Davita's stock price to reach $82.6250 in the next year. This suggests a possible upside of 32.8% from the stock's current price. View Analyst Price Targets for Davita.
What is the consensus analysts' recommendation for Davita?
10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Davita in the last year. There are currently 1 sell rating, 5 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Davita.
Has Davita been receiving favorable news coverage?
News articles about DVA stock have trended somewhat positive this week, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Davita earned a coverage optimism score of 1.3 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the stock's share price in the immediate future.
Who are some of Davita's key competitors?
Who are Davita's key executives?
Davita's management team includes the folowing people:
- Mr. Kent J. Thiry, Chairman & CEO (Age 62)
- Joel Ackerman, Chief Financial Officer (Age 53)
- Mr. James K. Hilger, Chief Accounting Officer (Age 56)
- Ms. Kathleen Alyce Waters, Chief Legal Officer (Age 50)
- Mr. Javier J. Rodriguez, Chief Exec. Officer of DaVita Kidney Care (Age 47)
Who are Davita's major shareholders?
Davita's stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (5.78%), OppenheimerFunds Inc. (2.57%), Dimensional Fund Advisors LP (1.55%), Bank of New York Mellon Corp (1.36%), FMR LLC (1.16%) and Manning & Napier Group LLC (1.06%). Company insiders that own Davita stock include Charles Berg, James K Hilger, Javier Rodriguez, Kent J Thiry, Leanne M Zumwalt, Pamela M Arway and William L Roper. View Institutional Ownership Trends for Davita.
Which institutional investors are selling Davita stock?
DVA stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Bank of New York Mellon Corp, Neuberger Berman Group LLC, Partner Fund Management L.P., Mitsubishi UFJ Trust & Banking Corp, DNB Asset Management AS, First Trust Advisors LP and WINTON GROUP Ltd. Company insiders that have sold Davita company stock in the last year include Charles Berg, James K Hilger, Javier Rodriguez, Kent J Thiry, Leanne M Zumwalt, Pamela M Arway and William L Roper. View Insider Buying and Selling for Davita.
Which institutional investors are buying Davita stock?
DVA stock was acquired by a variety of institutional investors in the last quarter, including Pendal Group Ltd, Glenmede Trust Co. NA, FMR LLC, Capital Fund Management S.A., OppenheimerFunds Inc., Bridgewater Associates LP, Point72 Asset Management L.P. and O Shaughnessy Asset Management LLC. View Insider Buying and Selling for Davita.
How do I buy shares of Davita?
Shares of DVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Davita's stock price today?
One share of DVA stock can currently be purchased for approximately $62.23.
How big of a company is Davita?
Davita has a market capitalization of $10.36 billion and generates $10.88 billion in revenue each year. The company earns $663.61 million in net income (profit) each year or $3.32 on an earnings per share basis. Davita employs 74,500 workers across the globe.
What is Davita's official website?
How can I contact Davita?
Davita's mailing address is 2000 16TH STREET, DENVER CO, 80202. The company can be reached via phone at 303-405-2100 or via email at [email protected]
MarketBeat Community Rating for Davita (NYSE DVA)
MarketBeat's community ratings are surveys of what our community members think about Davita and other stocks. Vote "Outperform" if you believe DVA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DVA will underperform the S&P 500 over the long term. You may vote once every thirty days.
